APOC3 and metabolic syndrome: In other words, subjects with both atherogenic dyslipidemia marked by high Apo CIII concentrations and a clinical history coherent with an elevated risk marked by high CHA2DS2-VASc score resulted at the highest risk of ischemic stroke/TIA in spite of anticoagulant treatment, thus being potentially the “best target” for more aggressive therapeutic approaches aiming at the reduction of cerebral ischemic events.